Loading...
Upcoming Cell And Gene Therapy Milestones Are Expected To Transform Long Term Royalty Prospects
AN
AnalystConsensusTarget
Not Invested
Based on Analyst Price Targets
Published
11 Dec 25
Views
29
11 Dec
US$1.06
AnalystConsensusTarget's Fair Value
US$6.68
84.1% undervalued intrinsic discount1Y
-52.9%7D
-2.8%1Y
-52.9%7D
-2.8%You can edit this narrative until Dec 12 2:05 PM. Then, changes will post as Updates.
Author's Valuation
US$6.6884.1% undervalued intrinsic discount
AnalystConsensusTarget Fair Value